Immunai Raised $60 million for Artificial Intelligence
Immunai a New York and Tel Aviv-based biotech company raised funding of $60 million and made it to a total of $80 million.
Immunai is planning to develop artificial intelligence to analyze human immunity and the company will use these funds in order to expand its capabilities and to discover, develop new theories and drug combinations.
The investments are made by Catalio Capital Management, Schusterman Family investment, and Dexcel Pharma.
Noam Solomon and his Co-founder and CTO Louis Both have a computer science background and with hat, Immunai has already demonstrated that its platform can identify optimal targets for existing therapies.
By partnering with pharmaceuticals, biotech, and academic leaders they are all set to achieve their targets.